India covid-19 infection patient Coronavirus India

Cipla to explore remdesivir multi-drug combination for Covid-19

Reading now: 193
www.pharmaceutical-technology.com

India-based Cipla has plans to explore the use of multi-drug combination, including Gilead Sciences’ investigational antiviral drug remdesivir, for the treatment of Covid-19 coronavirus infection.

In an interview with Livemint news agency, Cipla chief financial officer Kedar Upadhye said that the company intends to assess a combination of zinc, hydroxychloroquine, azithromycin, lopinavir-ritonavir and favipiravir, among other drugs.

Upadhye was quoted as saying: “We are trying all avenues. We are attempting to come to the service of patients and try to see which molecule is more effective.

We are trying through all ways. I think we will attack Covid-19 through multiple ways.” Cipla is among the five companies that entered a non-exclusive

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA